Safety of Nintedanib in Real World in China

The main objective of this study is to evaluate the incidence rates of adverse drug reactions (ADRs) and fatal adverse events (AEs) among idiopathic pulmonary fibrosis (IPF) patients in China who initiate nintedanib during the study period.

Inclusion Criteria:Patients who initiate nintedanib during the study periodPatients who initiate pirfenidone during the study periodPatients who use neither nintedanib nor pirfenidonePatients who were diagnosed with IPF according to the 2011 American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) guidelines in the past 3 months before recruitmentPatients who are 40 years old and above when enrolledPatients who are willing to participate in the study and sign the informed consent form